Loading patent…
AssigneeWisconsin Alumni Research Foundation
InventorsHector F. DeLuca, Connie M. Smith
Estimating the term…
This invention provides pharmaceutical uses for 2α-methyl-19-nor-20(S)-1α,25-dihydroxyvitamin D3. This compound is characterized by high bone calcium mobilization activity demonstrating preferential activity on bone. This results in a novel therapeutic agent for the treatment of diseases where bone formation is desired, particularly osteoporosis. This compound also exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis. This compound also increases both breaking strength and crushing strength of bones evidencing use in conjunction with bone replacement surgery such as hip and knee replacements.
A method of treating metabolic bone disease where it is desired to maintain or increase bone mass comprising administering to a patient with said disease an effective amount of 2α-methyl-19-nor-20(S)-1α,25-dihydroxyvitamin D3 having the formula:
A method of treating psoriasis comprising administering to a patient with psoriasis an effective amount of 2α-methyl-19-nor-20(S)-1α,25-dihydroxyvitamin D3 having the formula:
A method of treating leukemia, colon cancer, breast cancer or prostate cancer comprising administering to a patient with said disease an effective amount of 2α-methyl-19-nor-20(S)-1α,25-dihydroxyvitamin D3 having the formula:
A method of increasing the strength of a bone comprising administering to a patient in need of such treatment an effective amount of 2α-methyl-19-nor-20(S)-1α,25-dihydroxyvitamin D3 having the formula:
Dependencies are inferred from the claim text.